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ABSTRACT
Objectives: The present study was aimed to overcome the problems associated with the drug such as bioavailability, to reduce the dosage regimen, 
half–life, and to determine the appropriateness of niosomal formulation as a drug carrier.
Methods: The niosomal suspension was prepared by thin film technique, by varying ratios of span 60 and cholesterol and varying the concentration 
of span 60. The prepared four formulations were evaluated for various parameters.
Results: The optimized formulation had a vesicular size of 250-400 nm. Varying the concentration of span 60, the entrapment efficiency demonstrated 
that it had a considerable task. The highest entrapment efficiency was 95.3%. The kinetics study confirmed that the liberation of drug from the 
niosomal suspension is in a restricted manner. The statistical optimization showed that NS2 is the optimized formulation. The gastrointestinal 
enzymes showed no significant change in the release of drug from the formulation. The zone of inhibition showed that optimized formulation has 
a better activity than the marketed formulation. The MIC was found to be 0.05 mg, hence can be used as an efficient carrier for delivery of cefixime.
Conclusion: The present study concludes that the prepared niosomal suspension is a convenient and efficiency carrier for the delivery of antibacterial 
drug. Besides this, it provided controlled delivery of drug.
Keywords: Niosomes, Cholesterol, Thin film technique, Vesicular size, Controlled drug delivery.
INTRODUCTION
Noisomes are non-ionic surfactant of the alkyl or dialkyl polyglycerol 
ether class and cholesterol with subsequent hydration in aqueous media. 
These are lamellar structures that are microscopic in size. Structurally 
niosomes are bilayered in nature. On the basis of preparation methods 
used, niosomes may be unilayer or multilayer [1,2]. Depending on 
various factors such as stability and cost, the niosomes are considered 
ideal when compared with liposomes. For various routes such as 
topical, ophthalmic, and parenteral niosomes prove to be a potential and 
possible drug delivery mechanism [3]. It was prepared by the method 
of ether injection method, handshaking method (thin film hydration 
technique), sonication, microfluidization, multiple membrane extrusion 
method, reverse phase evaporation technique, transmembrane pH 
gradient (inside acidic) drug uptake process (remote loading), and the 
“Bubble” method [4-8].
Various factors affecting niosomal formulations are type of surfactant, 
drug and amount, charge and cholesterol content, osmotic stress due to 
resistance, and constitution of membrane [6,9-12].
The main aim of this project is to study about niosomal suspension which 
is emerging as a potential drug carrier, as a new drug delivery for the 
antibiotic drug cefixime. Therefore, the objective behind the study is to 




Pre-formulation investigations are to provide information on 
physicochemical and biopharmaceutical study properties of drug 
molecule, non-drug substance, and materials used for packaging as well 
as compressibility.
Identification of the drug
Melting point
The purity of the sample is indicated by the melting point so obtained. 
The melting point values can get lowered because of the presence of 
unwanted substances.
λmax of the drug
Using phosphate buffer, the absorption maximum of cefixime was 
obtained. A range of solutions (2-10 µg/ml) was scanned using UV 
spectrophotometer.
Solubility
To obtain a desirable concentration of the drug in the blood, solubility 
plays a major role [13]. Varying solvents were taken including 0.1N 
HCL, methanol, water, ethanol, and certain buffers such as phosphate 
buffer (7.4) to determine the solubility.
Partition coefficient of drug
Partition coefficient of cefixime in n-octanol-water was obtained.
Physical drug excipient compatibility
At 75% relative humidity and 40°C, the formulations were kept 
sealed for 30 days. Then, it was compared with the initial state for any 
occurrence of interaction.
Fourier transform infrared (FTIR) studies
With the help of infrared absorption spectral analysis (FTIR), the 
cefixime compressibility with individualized non-drug component 
and physical combination of the major formulation was produced. 
Spectral analysis using IR helped to identify any modification in the 
characters of the formulation when it was mixed with the non-drug 
substance.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i5.17189
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Formulation of niosomal suspension
Method
Niosomal suspension was prepared by thin film hydration method 
(Table I). The cholesterol and the surfactant were mixed and added in 
about 20 ml of chloroform into an evaporating flask of rotary evaporator 
and dipped in water bath at 300°C. It was then evaporated at very low 
pressure until it formed a dry thin film on the flask, which was then 
dissolved in 20 ml of phosphate buffer, and kept on a water bath at 450°C 
and 120 rpm rotation to hydrate the layers, later sonicated to obtain 
niosomal suspension. The prepared niosomal suspension was then 
stored in a tight container in refrigerator for further characterization [10].
Characterization of niosomal suspension
Vesicular size evaluation
Microscopic evaluation
A little amount of niosomal suspension was dissolved with 10-12 ml 
of phosphate buffer (pH 7.2). The distribution of niosomal suspension 
was shaken in regular intervals of time. When an drop of dispersion was 
microscopically observed, rounded vesicular constituents were seen 
with uniform small size at ×100.
Size and size distribution
Dynamic light scattering method was used to evaluate vesicular size 
distribution. The niosomal suspension was diluted with 10-12 ml 
distilled water with physical shaken. The temperature was fixed at 
20°C, refractive index at 1.333 viscosity, and 0.01 poise.
Scanning electron microscopy
Niosomal suspension was diluted with distilled water and was attached 
with the help of a glued double-faced carbon tape on an aluminum 
stub. With the help of a vacuum evaporator, the vesicular components 
covered with gold and were examined.
Entrapment efficiency
The niosomal suspension was sonicated after loading the drug along 
with the phosphate buffer and was centrifuged and separated. Assay 
was done at 288 nm to quantify cefixime.
Zeta potential determination
The ideal formulation’s zeta potential was obtained by Zetasizer.
In vitro drug release
It carried out for the four niosomal suspension formulations.
Activation of cellophane membrane
The cellophane membrane was activated first by dipping in hot water 
for 1 hr, and then membrane was immersed in ethanol for 30 minutes. 
The ethanol-immersed membrane was then transferred to acetate 
buffer of pH 4 and kept for overnight.
In vitro drug release studies in gastrointestinal pH
Three milliliters of niosomal suspension containing known amount of 
drug was taken in a cellophane membrane tied to one of the ends of 
an open-ended cylinder. The entire apparatus was immersed in 30 ml 
0.1 N HCL pH 1.2 and stirred at 370°C. Samples of definite amount were 
withdrawn at specific intervals of time (5, 10, 15, 30, 45, 60, 75, 90, 
105, and 120 minutes) and were analyzed by UV spectrophotometry at 
288 nm [11,12].
In vitro drug release studies in phosphate buffer pH 7.2
Using spectrophotometry, the percentage of drug released was 
obtained.
Statistical design of experiment
The software was used to perform the procedure for statistical 
optimization. The statistical optimization procedure was performed 
with the help of optimization software such as Statgraphics 
Centurion 16.
ANOVA study by one-way method
When the F value is higher than critical F value, the null hypothesis is 
rejected.
Study on the effect of gastrointestinal enzymes on the release of 
drug
The effect of the enzymes such as trypsin and pepsin was studied on 
the release of optimized formulation. 2 ml of niosomal suspension 
containing known amount of drug was taken in a cellophane membrane 
tied to one of the ends of an open-ended cylinder. The entire apparatus 
was immersed in 30 ml 0.1 N HCL pH 1.2 containing 0.25% pepsin and 
stirred at 370°C. Samples of definite amount were withdrawn at specific 
intervals of time (5, 10, 15, 30, 45, 60, 75, 90, 105, and 120 minutes) and 
were analyzed by UV spectrophotometry at 288 nm [13,14].
In vitro antibacterial activity
The in vitro antibacterial activity was performed using agar diffusion assay 
method. The microorganism employed was Escherichia coli and Klebsiella. 
The activity was performed on optimized formulation, marketed 
formulation (cefixime - oral suspension), and plain niosomal suspension.
Media and Chemicals
Media and chemicals were distilled water, 05% sodium chloride, 1.5% 
agar, 0.5% peptone, 0.3% beef extract/yeast extract, and pH adjusted to 
neutral (6.8) at 25°C.
Additional materials required
Additional materials required were standard microbiological supplies 
and apparatus such as biochemical reagents, incubators, incinerator/
autoclave, microscope, staining suppliers, slides, saline blank, and loops.
Comparison study of antibacterial activity of optimized 
formulation with marketed formulation
The antibacterial activity of the ideal formulation was studied against 
commercially available formulation of the drug. 0.1-0.2 ml of the 
test microorganism was inoculated into the freshly prepared sterile 
nutrient agar plates. Wells were arranged, and a positive control was 
also added to another well. The plates were incubated for 18-48 hrs 
at room temperature. After incubation, they were examined for the 
presence or absence of the growth [15,16].
Determination of minimum inhibitory concentration (MIC)
The bacterial activity was inhibited by the increase in the concentration 
of the sample. The MIC was taken at the lowest concentration that 
prevented the growth of the microorganisms [17].
Stability studies
The ideal formulation of NS2 was preserved for 45 days at two different 
temperatures 30±2°C and 4±2°C to evaluate chemical and physical 
stabilities. For 7, 15, 30, and 45 days, the formulation was evaluated for 
entrapment efficiency [18-20].
RESULT AND DISCUSSION
Melting point of the drug
In accordance with the monograph, the melting point of the drug was 
found (218-225°C).
λmax of the drug
The λmax of the drug was found to be 288 nm, and it was in agreement 
with the official standard as in Fig. 1.
The above parameters such as melting point, λmax, and FTIR showed 
that it was in accordance with the reference and hence pure sample of 
cefixime I.P.
Solubility of the drug
The pure drug solubility was compared with the standard sample, and 
it reveals that the pure drug is highly soluble in methanol (95%) and 
practically insoluble in water.
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Partition coefficient of the drug
The partition coefficient of the drug was found to be 3.2. This indicates 
that cefixime is practically insoluble in water and having high lipid 
solubility, so this can be incorporated into niosomes for the efficient 
transport.
Physical drug excipient compatibility
There were no incompatibilities or interaction between drug and 
excipients.
FTIR spectroscopy
From the spectra, it is evident that all the peaks in the FTIR of the drug 
are shown (Fig. 2) in the FTIR peak of the formulation. This finding 
confirms that cefixime does not interact with any of the ingredients of 
the niosomal suspension.
Analytical method
Calibration curve (Fig. 2) in phosphate buffer pH 7.2 shows the 
absorption reading of standard drug solution containing 2-10 µg/ml of 
drug in phosphate buffer (7.2) at a wavelength of 288 nm.
On the basis of this standard curve (Fig. 3), the calculations of drug 
contents and in vitro drug release are studied.
Characterization of niosomal suspension
• Vesicular size evaluation
• Microscopic evaluation
Dissolved niosomes from niosomal suspension were observed 
microscopically and found to be having similarity and uniformity in 
vesicle size.
Size and size distribution
When evaluated for vesicular size and size distribution, it showed that 
ionic concentration rise can increase the mean vesicular size which 
ranged between 215 and 400 nm. The niosomal suspensions formed by 
hydration were of uniform size as suggested by the low polydispersity 
index as shown in Fig. 4.
Scanning electron microscopy
Fig. 5 shows that the optimized formulation has a particle size between 
to be 250 and 400 nm.
Fig. 1: Absorption maxima of cefixime in phosphate buffer in phosphate buffer (pH = 7.2)
Fig. 2: Fourier transform infrared of cefixime, cholesterol, span 60, formulation
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Entrapment efficiency
Entrapment efficiency of these formulations was found considerable 
at p<0.05 (Fig. 6). Depicts the entrapment efficiency of the different 
formulations. NS2 has the highest entrapment efficiency.
Zeta potential determination
The zeta potential determination confirmed that the ideal formulation 
(NS2) illustrates that the sample is stable suspension.
In vitro release studies
Both in vivo and delivery system functioning inside the body can be 
predicted by the release profile of a drug. All the four formulations 
underwent in vitro release studies in stomach pH and intestinal pH. The 
release data represented in the graph in Figs. 7-9.
The in vitro release pattern of the four formulations in the Stomach pH 
was studied, and it was concluded that there is no significant release of 
drug in the stomach pH as the release is only 0.4%. The release profiles 
suggest that the release of drug occurs slowly and later immediate 
release. Therefore, the release first occurs slowly and then immediately 
due to penetration enhancement of nonionic surfactant.
Kinetic modeling of in vitro drug release
The in vitro drug liberation of NS2 was fitted into various kinetic 
equations, and the linearity of each plot was determined by the 
closeness of regression coefficient to unity. The kinetic study of the 
release data showed that NS2 showed Higuchi model as the best fit 
model. The linearity of Higuchi plots indicates that as the distance of 
the diffusion increases the release of drug will be at a slower pace. 
This concludes that the drug is being released from the inner side of 
niosomal suspension in a restricted method. Kinetic study of the drug 
release profile optimum formulations NS2 is shown, and the graphical 
representations are shown in Fig. 9.
Optimization of formulation by one-way ANOVA method
Analysis of variance was used to optimize the formulation; it was 
carried out at 95% confidence interval. The report is represented in 
Figa. 10 and 11.
ANOVA analysis report
The ANOVA of entrapment efficiency indicates that both surfactant and 
cholesterol are significant terms as the F values are above the critical F 
values and thus making the p<0.05 (threshold level).
There is a statistically significant difference between the means of the 
two variables at the 95.0% confidence level, represented in Fig. 12.
Study on the effect of gastrointestinal enzymes on the release of 
drug
In vitro antibacterial activity
a. Comparison study of antibacterial activity of the optimized 
formulation and marketed formulation by zone of inhibition.
 The optimized formulation NS2 was found to have better activity in 
both E. coli and Klebsiella than the marketed formulation of the drug 
(Table 2).
b. Determination of MIC of cefixime loaded niosomal suspension 
(Fig. 13).
The MIC of the optimized formulation was obtained.
Furthermore, the value is tabulated in Table 3.Fig. 3: Calibration in phosphate buffer pH 7.2
Fig. 4: Vesicular size of niosomal suspension of NS1, NS2, NS3, and NS4
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Fig. 5: Scanning electron microscopy of optimized formulation
Fig. 6: Representing entrapment efficiency of formulations
Fig. 7: In vitro release studies of NS1, NS2, NS3, and NS4 in pH 1.2
in the entrapment efficiency while kept for 45 days in both of these 
conditions represented in Fig. 14.
CONCLUSION
The current article was intended to build up an appropriate transporter 
for the delivery of cefixime, third-generation cephalosporin antibiotic 
drug to conquer the troubles associated with it, like the poor solubility, 
low bioavailability, and half-life of the drug, thereby increasing the 
duration of action and thereby increasing the half-life. The pre-
formulation studies were carried out; from the study, it was clear that 
it satisfy the entire characteristic for oral drug delivery. The partition 
coefficient of the drug confirmed that the drug is lipid soluble and 
hence confirmed that niosomal suspension may be a proficient for the 
delivery of drug. The niosomal suspension was prepared by thin film 
hydration technique by varying the concentration of surfactant, while 
keeping the concentration of cholesterol same. The characterization 
of the niosomal suspension was conducted and had a particle size of 
350-450 nm. In vitro drug release was done in both stomach pH and 
intestinal pH. The release in stomach pH was only 0.4%, while the 
release in intestinal pH was 57.72%. The effect of gastrointestinal tract 
enzymes such as pepsin and trypsin on the in vitro liberation of drug 
from the formulation was also carried out. It was found that there is 
no much significant effect of the enzymes on the release of the drug 
from the formulation. The kinetics study of the formulation follows 
Higuchi model which states that the distance of the diffusion increases 
the release of drug will be at a slower pace. This concludes that the 
drug is being released from the inner side of niosomal suspension in 
a controlled manner. The optimization was based on the entrapment 
efficiency and in vitro release studies. ANOVA showed that NS2 (Span 
60-300 mg and cholesterol - 200 mg) is the optimized formulation. 
In vitro antibacterial study against E. coli and Klebsiella revealed that 
the zone of inhibition higher than the marketed formulation. The MIC 
confirmed that the inhibitory concentration was much less 0.05 mg; 
hence, it can be used as a proficient transporter for the delivery of 
cefixime. The formulation was stable for about 45 days at two different 
temperatures. From the present study, it is clear that the surfactant at 
the medium level showed highest entrapment efficiency and release. 
The in vitro antibacterial activity showed that the activity is more 
than the marketed formulation and the MIC was much lower than the 
Stability studies
The optimized formulation at two temperatures, i.e. 30±2°C and 4±2°C 
were done for 45 days; it does not show any variation when studied 
against the newly prepared formulation. There is no major variation 
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Fig. 8: In vitro release studies of NS1, NS2, NS3, and NS4 in pH 7.2
Fig. 9: Zero order, first order, and Higuchi plot of NS2
Fig. 10: ANOVA analysis of entrapment efficiency
standard used. Thus, niosomal suspension is a promising carrier for 
the delivery of cefixime.
Table 1: Composition of formulation
Ingredients Formulation code
NS1 NS2 NS3 NS4
Surfactant (mg) 200 300 400 500
Cholesterol (mg) 200 200 200 200
Chloroform (ml) 20 20 20 20
Phosphate buffer (7.2) (ml) 20 20 20 20
Drug (mg) 20 20 20 20
200
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Table 2: Evaluation of in vitro antibacterial activity by zone of inhibition
Microorganism Concentration (µl/well) Zone of inhibition (mm)
Marketed formulation Optimized formulation Plain niosomes
E. coil 2 0 0 0
5 11 13 0
10 14 18 0
15 16 2 0
Klebsiella 2 0 0 0
5 1 14 0
10 12 16 0
15 14 19 0
E. coli: Escherichia coli
Table 3: Minimum inhibitory concentration of cefixime loaded 
niosomal suspension
Microorganisms Minimum inhibitory concentration (mg/ml)
Optimized formulation
E. coli 0.05 mg
Klebsiella 0.05 mg
E. coli: Escherichia coli
Fig. 12: Effect of enzymes in the in vitro release of optimized 
formulation
Fig. 13: Photograph of in vitro antibacterial activity of optimized 
formulation and photograph of in vitro antibacterial activity of 
optimized formulation
Fig. 14: Stability study of optimized formulation NS2
Fig. 11: ANOVA analysis of release study in vitro
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